Pfizer Suffers Setback In Lipitor Patent Re-Exam

Law360, New York (January 14, 2008, 12:00 AM EST) -- The U.S. Patent and Trademark Office has initially rejected the claims of Pfizer's basic patent for the cholesterol drug Lipitor, which brought in $3.2 billion in sales for the company in the third quarter of 2007.

Pfizer said that it would respond to the USPTO's rejection, and that an initial rejection was “not unusual” in the context of reexamination proceedings. The company also said that the patent, which covers Lipitor's active ingredient atorvastatin, would remain valid and enforceable throughout the reexamination process, which could take several...
To view the full article, register now.